[ad_1]
NOVA DÉLHI – The Indian Pharmaceutical Company Bharat Biotech said Tuesday the 9th that it will probably export its vaccine against COVID-19 for Brazil and the United Arab Emirates this week, a great success for the vaccine approved at home for emergency use with no data on the effectiveness of an advanced stage trial.
Bharat Biotech has already supplied millions of doses of Covaxin, developed with the state Indian Medical Research Council, to the government’s inoculation campaign, which is also committed to exporting locally manufactured vaccines as part of a diplomatic attack.
“Basically, yes,” a Bharat Biotech spokeswoman told Reuters when asked if exports to the two countries could start this week, local media reported.
The company is awaiting the results of an ongoing trial with 25,800 participants from India in March alone, but the country’s drug regulatory agency considers the vaccine to be safe and effective, despite criticism from doctors and health experts. A study of 26 participants showed that Covaxin is effective against the British variant of the coronavirus.
Bharat Biotech has also requested authorization to conduct an advanced stage trial of Covaxin in Brazil, which plans to import 8 million doses in February and another 12 million in March.
Bharat Biotech has also applied for authorization for emergency use in the Philippines. The company has supplied 5.5 million doses to the Indian government and is selling an additional 4.5 million, the spokeswoman added.
India also ordered another 10 million doses of the AstraZeneca vaccine from the Serum Institute of India (SII), a company spokesman told Reuters. IBS manufactures the vaccine primarily for low- and middle-income countries.
The two vaccines are used in what India ranks as the world’s largest immunization program to cover 300 million people in August, starting with healthcare workers and other workers and reaching the elderly and people with pre-existing diseases. in March.
IBS, which is the world’s largest vaccine manufacturer, had already provided 11 million doses to the inoculation campaign, which has covered 6.3 million front-line professionals since it began on January 16.
“The second order has already been received, there are 10 million doses,” said an SII spokesperson, adding that the figure is part of the 100 million doses that the company agreed to sell to the government for around $ 2.74 each.
The country’s drug regulatory agency said the Covishield IBS vaccine is about 72% effective.REUTERS
[ad_2]
